MK-2206 (free base)
Product Sizes
Get quote
£ POA
HY-10357-1EACH
About this Product
- SKU:
- HY-10357
- CAS Number:
- 1032349-93-1
- Extra Details:
- MK-2206 free base is an orally active pan-AKT inhibitor; with IC50 values of 8 nM; 12 nM and 65 nM against AKT1; AKT2 and AKT3; respectively. MK-2206 free base inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 free base induces G1-phase cell cycle arrest; apoptosis (apoptosis); epithelial-mesenchymal transition; fibroblast activation and extracellular matrix deposition. MK-2206 free base causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 free base can be used in research related to solid tumors; renal fibrosis and hypercholesterolemia[1][2][3][4].
- Molecular Weight:
- 407.47
- References:
- [1]Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37.|[2]Agarwal E, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 2014 Mar 1;14:145.|[3]Xing Y, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 Jul 5;21(1):78.|[4]Li Yan, et al. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009.|[5]Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
